Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 9

Mitochondrial dysfunction, oxidative stress, and major depressive disorder

Authors Tobe EH

Published Date April 2013 Volume 2013:9 Pages 567—573

DOI http://dx.doi.org/10.2147/NDT.S44282

Received 20 February 2013, Accepted 2 April 2013, Published 26 April 2013

Edward H Tobe

University of Medicine and Dentistry of New Jersey/School of Osteopathic Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, and Cooper Medical School of Rowan University, Camden, NJ, USA

Abstract: There is controversy about depression being a physical illness, in part because a reproducible, sensitive, and specific biologic marker is not available. However, there is evidence that mitochondrial dysfunction and oxidative stress may be associated with abnormal brain function and mood disorders, such as depression. This paper reviews selected human and animal studies providing evidence that intracellular mitochondrial metabolic dysfunction in specific brain regions is associated with major depressive disorder. This supports the hypothesis that chronic mitochondrial dysfunction in specific tissues may be associated with depression. Evaluation of mitochondrial dysfunction in specific tissues may broaden the perspective of depression beyond theories about neurotransmitters or receptor sites, and may explain the persistent signs and symptoms of depression.

Keywords: mitochondrial dysfunction, oxidative stress, major depressive disorder, depression

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Preventive treatment in migraine and the new US guidelines

Estemalik E, Tepper S

Neuropsychiatric Disease and Treatment 2013, 9:709-720

Published Date: 17 May 2013

Mood disorders and complementary and alternative medicine: a literature review

Qureshi NA, Al-Bedah AM

Neuropsychiatric Disease and Treatment 2013, 9:639-658

Published Date: 14 May 2013

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011